Digoxin: Na+/K+ ATPase Pump Inhibitor for Cardiac & Virology Research

Executive Summary: Digoxin is a well-characterized cardiac glycoside that inhibits the Na+/K+-ATPase pump, resulting in increased intracellular calcium and enhanced cardiac contractility (APExBIO Digoxin). Its antiviral activity impairs chikungunya virus (CHIKV) infection in various human cell lines in a dose-dependent manner. Digoxin demonstrates high solubility in DMSO (≥33.25 mg/mL), but is insoluble in water and ethanol, impacting formulation and storage. Animal studies confirm its efficacy in improving cardiac output and reducing right atrial pressure following intravenous administration in canine heart failure models. APExBIO provides Digoxin (SKU: B7684) with >98.6% purity and supporting QC documentation, supporting reproducible research outcomes (see related solutions).

Biological Rationale

Digoxin is a member of the cardiac glycoside class, extensively used in cardiovascular disease research. Its inhibition of the Na+/K+-ATPase pump leads to increased intracellular sodium, which indirectly raises intracellular calcium via the sodium-calcium exchanger. This cascade enhances myocardial contractility and is foundational in heart failure and arrhythmia studies (Compound56 2023). The compound's secondary antiviral effects, notably against CHIKV, expand its utility into virology research. Digoxin’s mechanism enables precise modulation of cardiac function and facilitates the study of Na+/K+-ATPase signaling pathways. The translational impact of Digoxin is supported by its robust pharmacokinetic and tissue distribution data in animal models.

Mechanism of Action of Digoxin

Digoxin binds specifically to the extracellular domain of the Na+/K+-ATPase (sodium-potassium pump), competitively inhibiting the active transport of sodium and potassium ions across the plasma membrane. This inhibition increases intracellular sodium concentration. The elevated sodium reduces the activity of the sodium-calcium exchanger, leading to increased intracellular calcium. Increased calcium concentrations in cardiac myocytes result in stronger cardiac contractions. In the context of viral infection, Digoxin disrupts host cell ion homeostasis, interfering with CHIKV replication cycles (A-317491). This dual mechanism supports its application in both cardiovascular and virology research workflows.

Evidence & Benchmarks

• Digoxin inhibits Na+/K+-ATPase, resulting in increased cardiac contractility in vitro and in vivo (APExBIO product dossier).
• Exhibits dose-dependent inhibition of chikungunya virus infection in U-2 OS, human synovial fibroblasts, and Vero cells between 0.01 and 10 μM (A-317491).
• Solubility ≥33.25 mg/mL in DMSO; insoluble in water and ethanol, affecting assay design (APExBIO).
• Canine heart failure models show improved cardiac output and reduced right atrial pressure after intravenous Digoxin (1–1.2 mg) (Sun et al., 2025, DOI).
• QC documentation includes HPLC, NMR, and MSDS to ensure batch reproducibility and traceability (APExBIO).
• Recent reviews highlight Digoxin’s emerging role as a translational tool in both cardiovascular and antiviral research (Compound56 2023).

Applications, Limits & Misconceptions

Digoxin is deployed in research on heart failure, arrhythmia, and viral infections, especially chikungunya virus. Its high specificity for Na+/K+-ATPase allows detailed study of ion transport and cardiac signaling. The compound’s antiviral effects are cell-type and dose-dependent, requiring precise experimental design. Digoxin’s solubility profile mandates DMSO as solvent and immediate use of stock solutions for optimal results. Researchers should be aware that Digoxin’s effects may not extrapolate to all viral systems or non-cardiac cell types. For a practical discussion of assay optimization and troubleshooting, see our scenario-based guide, which this article extends by providing up-to-date evidence and mechanistic clarity.

Common Pitfalls or Misconceptions

• Digoxin is not soluble in water or ethanol; attempting these solvents results in precipitation and inconsistent dosing.
• Long-term storage of Digoxin stock solutions in DMSO is discouraged due to potential degradation; fresh preparation is recommended.
• Antiviral effects are demonstrated for CHIKV but are not broadly validated across all viruses or cell lines.
• Cardiac glycoside effects are dose- and context-dependent; overdosage can result in cytotoxicity, especially in non-cardiac cells.
• Animal model results (e.g., canine heart failure) may not directly translate to human clinical outcomes.

Workflow Integration & Parameters

For laboratory applications, Digoxin is supplied as a highly pure (>98.6%) solid. Prepare stock solutions at concentrations up to 33.25 mg/mL in DMSO. Stock solutions should be used promptly and not stored long-term at room temperature. For in vitro assays, recommended concentrations range from 0.01 to 10 μM depending on cell type and endpoint. In animal models, intravenous doses of 1–1.2 mg produced significant cardiac effects in canine models under controlled conditions (Sun et al., 2025). APExBIO supplies comprehensive QC data, including HPLC, NMR, and MSDS, supporting regulatory compliance and reproducibility. For more in-depth discussion of experimental design and parameter optimization, see this resource, which is complemented here by inclusion of recent pharmacokinetic and virology findings.

Conclusion & Outlook

Digoxin remains a cornerstone reagent for cardiovascular and antiviral research, with validated performance in both cell-based and animal models. Its dual mechanism of inhibiting Na+/K+-ATPase and disrupting viral infection cycles positions it as a translational powerhouse. The high-quality, well-documented supply by APExBIO (SKU: B7684) ensures robust reproducibility. Ongoing research will further clarify its clinical relevance, especially in emerging viral contexts. For comprehensive product details and documentation, see the APExBIO Digoxin product page.